About
Orphan Diseases, Decoy Oligonucleotides
Areas of Focus
Categories
Small Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyDrug Delivery & Formulation
Team (11)
Clinical Trials (29)
View allTotal Trials
29
As Lead Sponsor
25
As Collaborator
4
Total Enrollment
3,807
By Phase
PHASE1/PHASE2: 9PHASE1: 7PHASE3: 3PHASE2: 8PHASE2/PHASE3: 2
By Status
COMPLETED: 23TERMINATED: 5WITHDRAWN: 1
Clinical Trials Pipeline29 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06257758Lead Sponsor
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
PHASE1/PHASE2Terminated
6 participants
Started: Jan 10, 2024 · Completed: Jan 1, 2025
NCT05700669Lead Sponsor
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
PHASE1/PHASE2Completed
3 participants
Started: Feb 20, 2023 · Completed: Oct 31, 2023
NCT03579628Lead Sponsor
AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
PHASE1Completed
33 participants
Started: Apr 5, 2018 · Completed: Feb 20, 2022
NCT02548806Lead Sponsor
Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers
PHASE1Completed
36 participants
Started: Sep 30, 2015 · Completed: Apr 30, 2016
NCT01655693Lead Sponsor
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
PHASE3Completed
397 participants
Started: Jun 30, 2012 · Completed: May 31, 2019
Locations (1)
Headquarters
Paris, France
Map
Loading map...